Sangamo Therapeutics, Inc.
Head Quarters
501 Canal Boulevard 501 Canal Boulevard USWebsite
http://www.sangamo.comIndustry
BiotechnologyEmployees
131Exchange
NASDAQSangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Lanphier O. Edward II on June 22, 1995 and is headquartered in Richmond, CA.
Key statistics
| Margins | Stock |
|---|---|
| Revenue per Employee | $0.00 |
| Current Ratio | 10 |
| Gross Margin (%) | 0.00% |
| Net Margin (%) | -0.89% |
| Returns | Stock |
| Sales | $18.00M |
| Sales Growth (% qtr vs. yr ago) | 0.00% |
| Net Income | -$13.00M |
| NI Growth (% qtr vs. yr ago) | 0.00% |
| Price/Sales | 7.71 |
| EPS | -$1.00 |